<code id='F38A27E0E7'></code><style id='F38A27E0E7'></style>
    • <acronym id='F38A27E0E7'></acronym>
      <center id='F38A27E0E7'><center id='F38A27E0E7'><tfoot id='F38A27E0E7'></tfoot></center><abbr id='F38A27E0E7'><dir id='F38A27E0E7'><tfoot id='F38A27E0E7'></tfoot><noframes id='F38A27E0E7'>

    • <optgroup id='F38A27E0E7'><strike id='F38A27E0E7'><sup id='F38A27E0E7'></sup></strike><code id='F38A27E0E7'></code></optgroup>
        1. <b id='F38A27E0E7'><label id='F38A27E0E7'><select id='F38A27E0E7'><dt id='F38A27E0E7'><span id='F38A27E0E7'></span></dt></select></label></b><u id='F38A27E0E7'></u>
          <i id='F38A27E0E7'><strike id='F38A27E0E7'><tt id='F38A27E0E7'><pre id='F38A27E0E7'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:546
          People in business and medical wardrobe in a table discussion — coverage from STAT
          Adobe

          R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private.

          Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

          advertisement

          In response to the offer, R1 asked New Mountain Capital to “engage in good faith discussions” with its largest investor — a partnership between Ascension, the large Catholic hospital system, and private equity firm TowerBrook Capital Partners. New Mountain Capital has since held several in-person meetings with Ascension and TowerBrook throughout February, but maintained its original offer for R1. No deal has been finalized yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Pharma patents targeted by Biden in move to slash drug prices
          Pharma patents targeted by Biden in move to slash drug prices

          PresidentBidenMANDELNGAN/AFPviaGettyImagesWASHINGTON—TheWhiteHouseisthrowingitssupportbehindacontrov

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

          STEFANIREYNOLDS/AFPviaGettyImagesUnderstandhowscience,healthpolicy,andmedicineshapetheworldeveryday.